ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ASCO-GU 2026 – Protara gets that sinking feeling
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
ASCO-GU 2026 – casdatifan starts to look competitive
Median PFS appears to back earlier response rate promise.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
MHNCS 2026 – J&J and Bicara face off
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
